Hepatocellular Carcinoma Clinical Trials in Guangzhou
6 recruitingGuangzhou, China
Showing 1–6 of 6 trials
Recruiting
Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
Biliary Tract CancerHepatocellular Carcinoma
AstraZeneca294 enrolled60 locationsNCT05775159
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 1Phase 2
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
Hepatocellular Carcinoma
AstraZeneca304 enrolled20 locationsNCT06795022
Recruiting
Phase 3
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Hepatocellular Carcinoma
AstraZeneca210 enrolled32 locationsNCT05557838